Search company, investor...

Founded Year

1993

Stage

Acquired | Acquired

Valuation

$0000 

About MoleculA

MoleculA was a Healthcare/Biotechnology company based in Herndon, Virginia. MoleculA was acquired in 2003.

Headquarters Location

13884 Park Center Road

Herndon, Virginia, 20171,

United States

703-481-9207

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

MoleculA Patents

MoleculA has filed 12 patents.

The 3 most popular patent topics include:

  • Data management
  • Database management systems
  • Business intelligence
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/26/2020

6/27/2023

Data management, Music software plugin architectures, Application programming interfaces, Database management systems, Information technology management

Grant

Application Date

5/26/2020

Grant Date

6/27/2023

Title

Related Topics

Data management, Music software plugin architectures, Application programming interfaces, Database management systems, Information technology management

Status

Grant

Latest MoleculA News

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecula...

Nov 1, 2022

BOSTON, MA — November 1, 2022 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer. MRT-2359 is a potent, selective and orally bioavailable GSPT1-directed MGD, designed to disrupt protein synthesis in MYC-driven tumors, and lead to anti-tumor activity.“MYC transcription factors are well-defined drivers of human cancers, and disrupting protein translation has emerged as a promising path to address this highly prevalent disease pathway. Dosing the first patient is a significant milestone in developing MRT-2359 as a therapeutic option for MYC-driven cancers,” said Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa. “We have designed our Phase 1 trial to move efficiently through dose escalation and, by focusing on tumor types where MYC expression is prevalent, to improve our chances of seeing early signals of clinical activity. We are encouraged by the strong preclinical data and hope that MRT-2359 will make a meaningful difference in the lives of patients.”

MoleculA Frequently Asked Questions (FAQ)

  • When was MoleculA founded?

    MoleculA was founded in 1993.

  • Where is MoleculA's headquarters?

    MoleculA's headquarters is located at 13884 Park Center Road, Herndon.

  • What is MoleculA's latest funding round?

    MoleculA's latest funding round is Acquired.

  • Who are the investors of MoleculA?

    Investors of MoleculA include International Aerospace Enterprises.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.